D.V. ARTEMOV, A.B. ZULKARNAEV

Moscow Regional scientific and research Clinical Institute named after M.F. Vladimirsky, 51/2 Schepkina Str., Moscow, Russian Federation, 129110

 Artemov D.V. — Nephrologist of the Therapeutic Department No. 1 of the Consultative Diagnostic Center, e-mail: anatom555@yandex.ru, ORCID 0000-0002-0753-967X

Zulkarnaev A.B. — D. Sc. (medicine), Professor of the Department of Transplantology, Nephrology and Artificial Organs of the Faculty of Continuing Medical Education, e-mail: anatom555@yandex.ru, ORCID 0000-0001-5405-7887

Study and analysis of the modern understanding of the pathogenesis, and approaches to the prevention and treatment of ischemic and reperfusion injury of a kidney transplant.

Material and methods. Study of specialized literature.

Result. The article highlights the main factors of the pathogenesis of ischemic syndrome/reperfusion of the renal allograft. Cellular, humoral, as well as non-specific mechanisms of development of kidney injury are described, and the main modern methods of influence on them are identified.

The conclusion. In the pathogenetic mechanisms of ischemic and reperfusion injury of a renal transplant, numerous cellular and humoral, and nonspecific factors as well play an important role. Further study of these mechanisms and development of pathogenetically substantiated methods of influencing them is one of the main vectors of the modern development of transplantology.

Key words: kidney transplantation, pathogenesis, ischemia, reperfusion, kidney injury, renal allograft.

(For citation: Artemov D.V., Zulkarnaev A.B. A contemporary view of pathogenesis and approaches to the prevention and treatment of ischemic and reperfusion injuries of a kidney transplant. Practical Medicine. 2018)

REFERENCES

1. Morariu A.M., Schuurs T.A., Leuvenink H.G. Early events in kidney donation: progression of endothelial activation, oxidative stress and tubular injury after brain death. Am J Transplant, 2008, vol. 8, no. 5, pp. 933–941.
2. Jayle C., Milinkevitch S., Favreau F. Protective role of selectin ligand inhibition in a large animal model of kidney ischemia-reperfusion injury. Kidney Int, 2006, vol. 69, no. 10, pp. 1749–1755.
3. Nemoto T., Burne M. J., Daniels F. Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure. Kidney Int, 2001, vol. 60, no. 6, pp. 2205–2214.
4. Bilenko M.V. Ishemicheskie i reperfuzionnye povrezhdeniya organov: molekulyarnye mekhanizmy, puti preduprezhdeniya i lecheniya [Ischemic and reperfusion organ damage: molecular mechanisms, ways to prevent and treat]. Moscow: Meditsina, 1989. 368 p.
5. Collard C.D., Gelman S. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology, 2001, vol. 94, no. 6, pp. 1133–1138.
6. Chok M.K., Ferlicot S., Conti M. Renoprotective potency of heme oxygenase-1 induction in rat renal ischemia-reperfusion. Inflamm Allergy Drug Targets, 2009, vol. 8, no. 4, pp. 252–259.
7. Katori M., Anselmo D.M., Busuttil R.W., Kupiec-Weglinski J.W. A novel strategy against ischem ia and reperfusion injury: cytoprotection with heme oxygenase system. Transpl. Immunol, 2002, vol. 9, no. 2–4, pp. 227–233.
8. Rabb H., Daniels F., O’Donnell M. Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice. Am. J. Physiol. Renal. Physiol, 2000, vol. 279, no. 3, pp. 525–531.
9. Krishnadasan B., Naidu B., Rosengart M. Decreased lung ischemia-reperfusion injury in rats after preoperative administration of cyclosporine and tacrolimus. J Thorac Cardiovasc Surg, 2002, vol.123, no. 4, pp. 756–767.
10. Nakayama Y., Nonoguchi H., Kiyama S. Intranephron distribution and regulation of endothelin-converting enzyme-1 in cyclosporin A-induced acute renal failure in rats. J Am Soc Nephrol, 1999, vol. 10, no. 3, pp. 562–571.
11. Beiras-Fernandez A., Chappell D., Hammer C., Thein E. Influence of polyclonal antithymocyte globulins upon ischemia-reperfusion injury in a non-human primate model. Transpl Immunol, 2006, vol. 15, no. 4, pp. 273–279.
12. Takada M., Chandraker A., Nadeau K.C. The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J. Clin. Invest, 1997, vol. 100, no. 5, pp. 1199–1203.
13. Furuichi K., Wada T., Iwata Y. CCR2 signaling contributes to ischemia-reperfusion injury in kidney. J Am Soc Nephrol, 2003, vol. 14, no. 10, pp. 2503–2015.
14. Katori M., Anselmo D.M., Busuttil R.W., Kupiec-Weglinski J.W. A novel strategy against ischem ia and reperfusion injury: cytoprotection with heme oxygenase system. Transpl. Immunol, 2002, vol. 9, no. 2–4, pp. 227–233.
15. Damman J, Daha M.R., van Son W.J. et al. Crosstalk between complement and Toll-like receptor activation in relation to donor brain death and renal ischemia-reperfusion injury. Am J Transplant, 2011, vol. 11, no. 4, pp. 660–669.
16. Furuichi K., Kaneko S., T Wada. Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidneydisease. Clin Exp Nephrol, 2009, vol. 13, no. 1, pp. 9–14.
17. El-Asir L., Wilson C.H., Talbot D. Interleukin 2 receptor blockers may directly inhibit lymphocyte mediated ischaemia reperfusion injury. Transpl Int, 2005, vol. 18, no. 9, p. 1116.
18. Cau J., Favreau F., Zhang K. et al. FR167653 improves renal recovery and decreases inflammation and fibrosis after renal ischemia reperfusion injury. J Vasc Surg, 2009, vol. 49, no. 3, pp. 728–740.
19. Simmons E.M., Himmelfarb J., Sezer M.T. et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int, 2004, vol. 65, no. 4, pp. 1357–1365.
20. Nakada T.A., Hirasawa H., Oda S. et al. Blood purification for hypercytokinemia. Transfus Apher Sci, 2006, vol. 35, no. 3, pp. 253–264.
21. Lewis A.G., Köhl G., Ma Q. et al. Pharmacological targeting of C5a receptors during organ preservation improves kidney graft survival. J Clin Exp Immunol, 2008, vol. 153, no. 1, pp. 117–126.
22. Polderman KH. Mechanisms of action, physiological effects, and complications of hypothermia. Crit Care Med, 2009, vol. 37 [suppl. 7], pp. 186–202.
23. Bagnenko S.F., Moysyuk Ya.G., Reznik O.N. The first experience of using hardware perfusion of kidneys obtained from asystolic donors to improve the results of transplantation. Vestnik transplantologii i iskusstvennykh organov, 2006, vol. 8, no. 3, pp. 9–13 (in Russ.).
24. Huang Y., Shan J., Wang C. et al. Can ischemic preconditioning alone really protect organs from ischemia reperfusion injury in transplantation. Transpl Immunol, 2009, vol. 20, no. 3, pp. 127–131.
25. Salahudeen A.K., May W. Reduction in cold ischemia time of renal allografts in the United States over the last decade. Transplant Proc, 2008, vol. 40, no. 5, pp. 1285–1289.
26. Zaouali M.A., Ben Abdennebi H., Padrissa-Altés S. et al. Pharmacological strategies against cold ischemia reperfusion injury. Expert Opin Pharmacother, 2010, vol. 11, №4, pp. 537–555.